BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Orencia abatacept regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against Orencia abatacept from Bristol-Myers as second-line therapy in combination with methotrexate to treat moderate to severe rheumatoid arthritis. In its submission to the agency, Bristol-Myers acknowledged that IV Orencia would not be as cost-effective when compared to subcutaneous RA drugs Humira adalimumab, Enbrel etanercept and the generic certolizumab pegol, drugs which NICE already recommends for...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >